NCT04529863View on ClinicalTrials.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept

CompletedOBSERVATIONAL
Enrollment

30,432

Participants

Timeline

Start Date

August 17, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tocilizumab

Tocilizumab claim is used as the reference group.

DRUG

Abatacept

Abatacept claim is used as the exposure group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Rutgers University

OTHER

collaborator

Johns Hopkins University

OTHER

lead

Brigham and Women's Hospital

OTHER

NCT04529863 - Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept | Biotech Hunter | Biotech Hunter